The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc Natl Acad Sci USA

Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 715 Albany Street, Boston, MA 02118-2932, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 03/2005; 102(5):1548-53. DOI: 10.1073/pnas.0409460102
Source: PubMed


The vast majority of eukaryotes (fungi, plants, animals, slime mold, and euglena) synthesize Asn-linked glycans (Alg) by means of a lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3. Knowledge of this pathway is important because defects in the glycosyltransferases (Alg1-Alg12 and others not yet identified), which make dolichol-PP-glycans, lead to numerous congenital disorders of glycosylation. Here we used bioinformatic and experimental methods to characterize Alg glycosyltransferases and dolichol-PP-glycans of diverse protists, including many human pathogens, with the following major conclusions. First, it is demonstrated that common ancestry is a useful method of predicting the Alg glycosyltransferase inventory of each eukaryote. Second, in the vast majority of cases, this inventory accurately predicts the dolichol-PP-glycans observed. Third, Alg glycosyltransferases are missing in sets from each organism (e.g., all of the glycosyltransferases that add glucose and mannose are absent from Giardia and Plasmodium). Fourth, dolichol-PP-GlcNAc2Man5 (present in Entamoeba and Trichomonas) and dolichol-PP- and N-linked GlcNAc2 (present in Giardia) have not been identified previously in wild-type organisms. Finally, the present diversity of protist and fungal dolichol-PP-linked glycans appears to result from secondary loss of glycosyltransferases from a common ancestor that contained the complete set of Alg glycosyltransferases.

Download full-text


Available from: Daniel J Kelleher,
  • Source
    • "R e c o n s t r u c t i n g t h e d o l i c h o l p a t h w a y o f n a t i v e N -l i n k e d g l y c o s y l a t i o n P. pastoris native N-glycosylation begins in the ER with a 14-residue sugar that contains 3 glucose (Glc), 9 mannose (Man), and 2 N-acetylglucosamine (GlcNAc) residues (Fig. 1), which are attached to a dolichol carrier (Samuelson et al., 2005). This core lipid-linked oligosaccharide, (glucosyl) 3 (mannosyl) 9 -(N-acetylglucosaminyl) 2 -diphosphodolichol is subsequently transferred by an oligosaccharyltransferase (OST) to asparagine residues in a protein (Karaoglu et al., 1997). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pichia pastoris is used for commercial production of human therapeutic proteins, and genome-scale models of P. pastoris metabolism have been generated in the past to study the metabolism and associated protein production by this yeast. A major challenge with clinical usage of recombinant proteins produced by P. pastoris is the difference in N-glycosylation of proteins produced by humans and this yeast. However, through metabolic engineering a P. pastoris strain capable of producing humanized N-glycosylated proteins was constructed. The current genome-scale models of P. pastoris do not address native nor humanized N-glycosylation, and we therefore developed ihGlycopastoris, an extension to the iLC915 model with both native and humanized N-glycosylation for recombinant protein production, but also an estimation of N-glycosylation of P. pastoris native proteins. This new model gives a better predictions of protein yield, demonstrates the effect of the different types of N-glycosylation of protein yield, and can be used to predict potential targets for strain improvement. The model represents a step towards a more complete description of protein production in P. pastoris, which is required for using these models to understand and optimize protein production processes. This article is protected by copyright. All rights reserved.
    Biotechnology and Bioengineering 10/2015; DOI:10.1002/bit.25863 · 4.13 Impact Factor
    • "Rapid nuclear and chloroplast transformation of microalgae into stable lines, safety of algal products, advances in engineering of photosynthesis and cell metabolism, and the ability to grow in contained photobioreactors with controlled culture conditions make the microalgae platform a highly promising biotechnological approach (Rosenberg et al. 2008; Ugwu et al. 2008). Furthermore, the ability of chloroplasts for complex protein folding and disulfide bond formation in the absence of posttranslational N-linked protein glycosylation (Nugent and Joyce 2005) is advantageous for the production of recombinant proteins that do not display N-linked glycans in their native host, such as Plasmodium antigens (Samuelson et al. 2005). The most commonly used species of algae, Chlamydomonas reinhardtii, has been used to produce monoclonal antibodies (Tran et al. 2009), therapeutic proteins (Rasala and Mayfield 2011), and subunit vaccines (Dauvillée et al. 2010) in chloroplasts. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite decades of effort battling against malaria, the disease is still a major cause of morbidity and mortality. Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. In the 1950s, Huff et al. first demonstrated the induction of transmission-blocking immunity in chickens by repeated immunizations with Plasmodium gallinaceum-infected red blood cells. Since then, significant progress has been made in identification of parasite antigens responsible for transmission-blocking activity. Recombinant technologies accelerated evaluation of these antigens as vaccine candidates, and it is possible to induce effective transmission-blocking immunity in humans both by natural infection and now by immunization with recombinant vaccines. This chapter reviews the efforts to produce TBVs, summarizes the current status and advances and discusses the remaining challenges and approaches. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Advances in Parasitology 06/2015; 89:109-152. DOI:10.1016/bs.apar.2015.04.001 · 6.23 Impact Factor
  • Source
    • "Rapid production, scalability and cost efficiency are the major advantages of such systems, making them attractive for vaccine development and manufacturing (Rybicki, 2010; Yusibov et al., 2011), particularly when short production cycles are required to address new pathogen strains emerging due to polymorphisms, genetic drift and the evolution of pathogen populations, resulting in sudden pandemics. Because the genus Plasmodium lacks essential glycosyltransferases (von Itzstein et al., 2008; Samuelson et al., 2005), P. falciparum proteins do not carry N-linked glycans in the native context. Nevertheless, several P. falciparum proteins contain NxS/T motifs that are targets for N-linked glycosylation when these proteins are expressed in heterologous eukaryotic hosts (Kedees et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the most promising malaria vaccine candidate antigens is the Plasmodium falciparum apical membrane antigen 1 (PfAMA1). Several studies have shown that this blood-stage antigen can induce strong parasite growth inhibitory antibody responses. PfAMA1 contains up to six recognition sites for N-linked glycosylation, a post-translational modification that is absent in P. falciparum. To prevent any potential negative impact of N-glycosylation, the recognition sites have been knocked out in most PfAMA1 variants expressed in eukaryotic hosts. However, N-linked glycosylation may increase efficacy by improving immunogenicity and/or focusing the response towards relevant epitopes by glycan masking. We describe the production of glycosylated and nonglycosylated PfAMA1 in Nicotiana benthamiana and its detailed characterization in terms of yield, integrity and protective efficacy. Both PfAMA1 variants accumulated to high levels (>510 μg/g fresh leaf weight) after transient expression, and high-mannose-type N-glycans were confirmed for the glycosylated variant. No significant differences between the N. benthamiana and Pichia pastoris PfAMA1 variants were detected in conformation-sensitive ligand-binding studies. Specific titres of >2 × 106 were induced in rabbits, and strong reactivity with P. falciparum schizonts was observed in immunofluorescence assays, as well as up to 100% parasite growth inhibition for both variants, with IC50 values of ~35 μg/mL. Competition assays indicated that a number of epitopes were shielded from immune recognition by N-glycans, warranting further studies to determine how glycosylation can be used for the directed targeting of immune responses. These results highlight the potential of plant transient expression systems as a production platform for vaccine candidates.
    Plant Biotechnology Journal 09/2014; 13(2). DOI:10.1111/pbi.12255 · 5.75 Impact Factor
Show more